Traversa Sergio

Chief Executive Officer, DirectorRELMADA THERAPEUTICS, INC. (RLMD) · full profile →Form 4 · filed Jul 5, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$560K
Net Open-Market Flow
-$560K
Transactions
9
7 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2022Option exercise(M)14K$16.00$220K103K
Jul 1, 2022Sell(S)4K$18.32$75K89K
Jul 1, 2022Sell(S)9K$18.45$163K93K
Jul 1, 2022Sell(S)839$18.48$16K102K
Jun 30, 2022Sell(S)11K$19.01$203K89K
Jun 30, 2022Sell(S)5K$19.37$103K99K
Jun 30, 2022Option exercise(M)16K$16.00$256K105K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2022Option exercise(M)14K$00
Jun 30, 2022Option exercise(M)16K$014K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-22-037231) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about RLMD insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001213900-22-037231"
Ask your agent
Use Arkolith to summarize insider buying and selling at RELMADA THERAPEUTICS, INC.
over the last 90 days and cite the filings.